March 4, 2008
Provectus Pharmaceuticals Receives US Patent Allowance to Provide Further Protection for Novel Photodynamic Drug PH-12
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB:
PVCT,
http://www.pvct.com),
a development-stage oncology and dermatology biopharmaceutical company, has received allowance of a second US patent application protecting a novel photoactive analog of its lead photodynamic product PH-10, from the United States Patent and Trademark Office (USPTO). The pending patent covers systemic use of the drug, PH-12, for photodynamic treatment of cancer, skin diseases, and other tissue disorders using visible light activation.
Read the complete article here.
February 26, 2008
Provectus Pharmaceuticals Receives Patent Allowances in Europe and China
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB:
PVCT,
http://www.pvct.com),
a development-stage oncology and dermatology biopharmaceutical company, has received allowance of its patent applications in Europe and China covering diagnostic use of PV-10 and a number of related agents in CT and MRI imaging. The pending patents cover products for diagnosis of cancer and other serious diseases.
Read the complete article here.
January 14, 2008
Provectus Pharmaceuticals Receives Patent Allowance in India
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB:
PVCT,
http://www.pvct.com),
a development-stage oncology and dermatology biopharmaceutical company, has received allowance of its patent application in India covering its lead dermatology agent, PH-10, along with a number of related agents. The pending patent covers topical products for treatment of skin diseases such as psoriasis and eczema. Additionally, a range of active compounds are protected, each related to the active ingredient in PH-10.
Read the complete article here.
January 9, 2008
Provectus Pharmaceuticals CEO Craig Dees, PhD Issues Executive Overview Letter
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Craig Dees, PhD, chief executive officer of Provectus Pharmaceuticals, Inc.
(OTCBB:
PVCT,
http://www.pvct.com),
has published his 2007 executive overview statement. The following letter from Dr. Dees was posted on the Company's website this morning. Additionally, management will present to institutions and retail brokers in Boston, Chicago, New York, and other cities throughout 2008 to increase investor awareness and visibility.
Read the complete article here.
December 18, 2007
Provectus Pharmaceuticals Adds Second Center to Phase 2 Clinical Trial of PV-10
KNOXVILLE, Tenn.--(BUSINESS WIRE)-- Provectus Pharmaceuticals, Inc. (OTCBB:
PVCT,
http://www.pvct.com)
has begun recruitment for its Phase 2 clinical trial of the Company's lead oncology agent PV-10 at a second major center, now covering Brisbane, Australia in addition to Sydney, Australia. Over the next several months, the Company expects to continue expansion of the study to include sites in most major population centers in Australia as well as several sites in the United States.
Read the complete article here.
December 11, 2007
Provectus Pharmaceuticals Receives Patent in India for Lead Oncology Product
KNOXVILLE, Tenn.--(BUSINESS WIRE)-- Provectus Pharmaceuticals, Inc. (OTCBB:
PVCT,
http://www.pvct.com)
has received a patent in India protecting its lead oncology agent, PV-10, along with a number of related agents.
Read the complete article here.
